Sign inJoin waitlistJoin the waitlist

Onyema Ogbuagu

Associate Program Director · Yale-New Haven Hospital

Credentials: · · · · · · · ·

History

Yale-New Haven Hospital
Present
Yale Institute for Global Health
Present
Yale-New Haven Hospital
Present

Infectious Disease
Yale School of Medicine
2010–2012
Icahn School of Medicine at Mount Sinai
2006–2010
Mount Sinai School of Medicine
2007–2010
University of Calabar
2000–2003

Research

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial
JAMA · 2020 · 944 citations
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report
Case report · Nature Communications · 2022 · 263 citations
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
New England Journal of Medicine · 2025 · 227 citations

Jessica Tuan
12 papers · 6 as a fellow
MR
Martin Rhee
6 papers
Elijah Paintsil
5 papers
Jared Baeten
5 papers
Merceditas Villanueva
5 papers
SS
Sorana Segal-Maurer
5 papers
Perry Tiberio
4 papers · 4 as a resident
Arit Esu
3 papers
Brinda Emu
3 papers
CC
Christoph Carter
3 papers
GF
Gerald Friedland
3 papers
Heidi Zapata
3 papers

Clinical trials

A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
Principal investigator · Withdrawn · Phase 4
Yale University
2021
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
Site PI · Recruiting · Phase 3
ViiV Healthcare
2026–2029
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
Site PI · Recruiting · Phase 2
ViiV Healthcare
2026–2028